Business
Perimeter Announces Proposed Public Offering of Units
Perimeter Announces Proposed Public Offering of Units Canada NewsWire ...
About this update from Perimeter Medical Imaging Ai Inc
[{"type":"text","content":"\n\n\n\n Perimeter Announces Proposed Public Offering of Units\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n\n\n\n\n\n\n\n PRELIMINARY PROSPECTUS ACCESSIBLE ON SEDAR+\n \n\n\n\n\n /NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN\n \n THE UNITED STATES\n \n /\n \n\n\n\n\n TORONTO\n \n and\n \n DALLAS\n \n\n ,\n \n\n March 27, 2025\n \n\n /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) (\"\n \n Perimeter\n \n \" or the \"\n \n Company\n \n \"), a commercial-stage medical technology company, announced today that it has filed a preliminary short form prospectus (the \"\n \n Preliminary Prospectus\n \n \") with the securities regulatory authorities in the Provinces of\n \n British Columbia\n \n ,\n \n Alberta\n \n and\n \n Ontario\n \n in connection with an offering of units of the Company (\"\n \n Units\n \n \"), with each Unit consisting of one common share and one common share purchase warrant (the \"\n \n Offering\n \n \"). The Offering is expected to be completed on a reasonable \"best efforts\" agency basis pursuant to an agency agreement (the \"\n \n Agency Agreement\n \n \") to be entered into between the Company and A.G.P. Canada Investments ULC (the \"\n \n Agent\n \n \"). The number of Units to be distributed, the price of each Unit and the exercise price and the expiry date of each warrant will be determined by negotiation between the Company and the Agent in the context of the market with final terms to be determined at the time of pricing.\n \n\n The Company intends to use the net proceeds from the Offering to continue the commercialization of its technology, establish clinical evidence and continue product development. The Company also intends to use the net proceeds for working capital and other general corporate purposes.\n \n\n The Company will pay to the Agent a cash fee equal to 7.0% of the gross proceeds raised under the Offering, and grant the Agents compensation options equal to 5.0% of the number of Units issued under the Offering...